An increased CALR+/7-AAD− cell population was documented in sensitive ALK-positive ALCL cell lines (K299, SUP-M2) after the administration of crizotinib and lorlatinib (0.5 μM and 0.1 μM, respectively), when compared to the untreated conditions (Figure 1A,B). Here, CALR is linked to anaplastic large cell lymphoma.